Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]

Vaccine

Volumn 30, Issue 15, 2012, Pages 2535-2542

  Savard, Christian ^a   Laliberté Gagné, Marie ève ^a   Babin, Cindy ^a   Bolduc, Marilène ^a   Guérin, Annie ^a   Drouin, Karine ^a   Forget, Marie Andrée ^b   Majeau, Nathalie ^a   Lapointe, Réjean ^b   Leclerc, Denis ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Adjuvant; High avidity; Influenza; Vaccination; VLP

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; NUCLEOPROTEIN; PAPAYA MOSAIC VIRUS LIKE PARTICLE ANP1 FUSION PROTEIN; PAPAYA MOSAIC VIRUS LIKE PARTICLE ANP2 FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS EXCRETION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CAPSID PROTEINS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; ORTHOMYXOVIRIDAE INFECTIONS; POTEXVIRUS; RECOMBINANT FUSION PROTEINS; RNA-BINDING PROTEINS; TH1 CELLS; VIRAL CORE PROTEINS;

EID: 84858277153     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.085     Document Type: Article

References (62)

1. Ilyinskii P.O., Thoidis G., Shneider A.M. Development of a vaccine against pandemic influenza viruses: current status and perspectives. Int Rev Immunol 2008, 27(6):392-426.
2. Nichol K.L. Efficacy and effectiveness of influenza vaccination. Vaccine 2008, 26(Suppl. 4):D17-D22.
3. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G [IgG] but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995, 69(4):2075-2081.
4. Rimmelzwaan G.F., McElhaney J.E. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008, 26(Suppl. 4):D41-D44.
5. Schulman J.L., Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J Bacteriol 1965, 89:170-174.
6. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994, 152(4):1653-1661.
7. Epstein S.L. Control of influenza virus infection by immunity to conserved viral features. Expert Rev Antiinfect Ther 2003, 1(4):627-638.
8. Altmuller A., Fitch W.M., Scholtissek C. Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses. J Gen Virol 1989, 70(8):2111-2119.
9. Gorman O.T., Bean W.J., Kawaoka Y., Webster R.G. Evolution of the nucleoprotein gene of influenza A virus. J Virol 1990, 64(4):1487-1497.
10. Scholtissek C., Ludwig S., Fitch W.M. Analysis of influenza A virus nucleoproteins for the assessment of molecular genetic mechanisms leading to new phylogenetic virus lineages. Arch Virol 1993, 131(3-4):237-250.
11. Shu L.L., Bean W.J., Webster R.G. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol 1993, 67(5):2723-2729.
12. Townsend A.R., Skehel J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 1984, 160(2):552-563.
13. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985, 82(March (6)):1785-1789.
14. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986, 67(4):719-726.
15. Chen W., Anton L.C., Bennink J.R., Yewdell J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000, 12(1):83-93.
16. Haanen J.B., Wolkers M.C., Kruisbeek A.M., Schumacher T.N. Selective expansion of cross-reactive CD8[+] memory T cells by viral variants. J Exp Med 1999, 190(9):1319-1328.
17. Taylor P.M., Askonas B.A. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986, 58(July (3)):417-420.
18. Gschoesser C., Almanzar G., Hainz U., Ortin J., Schonitzer D., Schild H., et al. CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine 2002, 20(31-32):3731-3738.
19. Yap K.L., Ada G.L. The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand J Immunol 1978, 8(5):413-420.
20. Wells M.A., Ennis F.A., Albrecht P. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol 1981, 126(3):1042-1046.
21. Lukacher A.E., Braciale V.L., Braciale T.J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984, 160(3):814-826.
22. Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol 1997, 158(3):1222-1230.
23. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998, 72(7):5648-5653.
24. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008, 181(6):4168-4176.
25. Tite J.P., Hughes-Jenkins C., O'Callaghan D., Dougan G., Russell S.M., Gao X.M., et al. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 1990, 71(2):202-207.
26. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 1996, 156(10):3892-3900.
27. Guo L., Zheng M., Ding Y., Li D., Yang Z., Wang H., et al. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol 2010, 155(11):1765-1775.
28. Denis J., Majeau N., Acosta-Ramirez E., Savard C., Bedard M.C., Simard S., et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007, 363(1):59-68.
29. Leclerc D., Beauseigle D., Denis J., Morin H., Pare C., Lamarre A., et al. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J Virol 2007, 81(3):1319-1326.
30. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol 2008, 82(2):785-794.
31. Tremblay M.H., Majeau N., Gagne M.E., Lecours K., Morin H., Duvignaud J.B., et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J 2006, 273(1):14-25.
32. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus [PapMV] vaccine platform. Vaccine 2008, 26(27-28):3395-3403.
33. Savard C., Guérin A., Drouin K., Bolduc M., Laliberté-Gagné M.E., Dumas M.C., et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. Plos One 2011, 6:e21522.
34. Terskikh A.V., Le Doussal J.M., Crameri R., Fisch I., Mach J.P., Kajava A.V. " Peptabody" : a new type of high avidity binding protein. Proc Natl Acad Sci USA 1997, 94(5):1663-1668.
35. Morin H., Tremblay M.H., Plante E., Pare C., Majeau N., Hogue R., et al. High avidity binding of engineered papaya mosaic virus virus-like particles to resting spores of Plasmodiophora brassicae. J Biotechnol 2007, 128(2):423-434.
36. Latterich M., Corbeil J. Label-free detection of biomolecular interactions in real time with a nano-porous silicon-based detection method. Proteome Sci 2008, 6:31.
37. Stuart-Harris C. A neurotropic strain of human influenza virus. Lancet 1939, 1:497-499.
38. Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006, 11(8):971-976.
39. Abed Y., Goyette N., Boivin G. Generation and characterization of recombinant influenza A [H1N1] viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 2005, 49(2):556-559.
40. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-1749.
41. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 1998, 72(2):1491-1496.
42. Epstein S.L., Tumpey T.M., Misplon J.A., Lo C.Y., Cooper L.A., Subbarao K., et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002, 8(8):796-801.
43. Luo M., Tao P., Li J., Zhou S., Guo D., Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virol Methods 2008, 154(1-2):121-127.
44. Andrew M.E., Coupar B.E., Boyle D.B., Ada G.L. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol 1987, 25(1):21-28.
45. Webster R.G., Kawaoka Y., Taylor J., Weinberg R., Paoletti E. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991, 9(5):303-308.
46. Wesley R.D., Tang M., Lager K.M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 2004, 22(25-26):3427-3434.
47. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23(46-47):5404-5410.
48. Altstein A.D., Gitelman A.K., Smirnov Y.A., Piskareva L.M., Zakharova L.G., Pashvykina G.V., et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol 2006, 151(5):921-931.
49. Roy S., Kobinger G.P., Lin J., Figueredo J., Calcedo R., Kobasa D., et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007, 25(39-40):6845-6851.
50. Barefoot B.E., Sample C.J., Ramsburg E.A. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin Vaccine Immunol 2009, 16(4):488-498.
51. Wraith D.C., Vessey A.E., Askonas B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 1987, 68(2):433-440.
52. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.
53. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40(1):60-65.
54. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262(5138):1448-1451.
55. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20(25-26):3104-3112.
56. Chackerian B., Lowy D.R., Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001, 108(3):415-423.
57. Coutelier J.P., van der Logt J.T., Heessen F.W., Warnier G., Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987, 165(1):64-69.
58. Hocart M.J., Mackenzie J.S., Stewart G.A. The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 1989, 70(9):2439-2448.
59. Zheng B., Zhang Y., He H., Marinova E., Switzer K., Wansley D., et al. Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. J Immunol 2007, 179(9):6153-6159.
60. Stitz L., Schmitz C., Binder D., Zinkernagel R., Paoletti E., Becht H. Characterization and immunological properties of influenza A virus nucleoprotein [NP]: cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. J Gen Virol 1990, 71(5):1169-1179.
61. Epstein S.L., Lo C.Y., Misplon J.A., Bennink J.R. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998, 160(1):322-327.
62. McMichael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol 1994, 189:75-91.